InsiderTrades

Form 4 for AVTX Avalo Therapeutics, Inc.

Accepted 2026-05-19 16:10:08 ET · period of report 2026-05-15 · accession 0001918845-26-000012 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DT 2026-05-19 16:10 2026-05-15 AVTX Doyle Mittie Chief Medical Off M - OptEx $12.65 +3,000 6,622 +83% +$38.0K
DT 2026-05-19 16:10 2026-05-15 AVTX Doyle Mittie Chief Medical Off S - Sale+OE $18.76 -3,000 3,622 -45% -$56.3K
DT 2026-05-19 16:10 2026-05-15 AVTX Doyle Mittie Chief Medical Off M - OptEx $0.00 -3,000 128.6K -2% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-05-15 M A 3,000 $12.65 6,622 D — — (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
2 Common Common Stock 2026-05-15 S D 3,000 $18.76 3,622 D — — (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
3 Derivative Stock Option (Right to Buy) 2026-05-15 M D 3,000 $0.00 128,625 D $12.65 · — to 2034-07-15 3,000 Common Stock (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. (F2) The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.